[1] Uslaner JM, Smith SM, Huszar SL, et al. Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants[J]. Psychopharmacology , 2009, 206(4): 641-651. [2] Drago A, Crisafulli C, Sidoti A, et al. The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes[J]. Prog Neurobiol, 2011, 94(4): 418-460. [3] Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment[J]. Psychopharmacology, 2011,213(2/3): 289-305. [4] 汪春运. 谷氨酸与精神药理[J]. 医药导报, 2009, 28(5): 622-624. [5] Stefani MR, Moghaddam B. Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia[J]. Biol Psychiatry, 2005, 57(4): 433-436. [6] Rujescu D, Bender A, Keck M, et al. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities [J]. Biol Psychiatry, 2006, 59(8): 721-729. [7] Wedzony K, Fijal K, Mackowiak M, et al. Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia[J]. Neuroscience, 2008, 153(4): 1370-1379. [8] 刘勇,唐亚梅, 蒲唯丹, 等. MK-801诱导的精神分裂症发育模型大鼠脑组织DA、DOPAC、Glu 和GABA浓度的变化[J]. 中南大学学报:医学版, 2011, 36(8): 712-719. [9] 倪尉, 周和平, 项光亚, 等. 非典型抗精神病药物的研究进展[J]. 医药导报, 2010, 29(3): 342-346. [10] Cai HL, Fang PF, Li HD, et al. Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment[J]. Psychiatry Res, 2011, 188 (2): 197-202. [11] Cai HL, Fang PF, Li HD, et al. Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment[J]. Psychiatry Res, 2011, 188 (2): 197-202. [12] Wang C, Anastasio N, Popov V, et al. Blockade of N-methyl-D-aspartate receptors by phencyclidine causes the loss of corticostriatal neurons[J]. Neuroscience, 2004, 125(2): 473-483. [13] Basta-Kaim A, Fijaŀ K, Budziszewska B, et al. Prenatal lipopolysaccharide treatment enhances MK-801-induced psychotomimetic effects in rats[J]. Pharmacol Biochem Behav, 2011, 98(2): 241-249. [14] Ohuoha DC, Hyde TM, Kleinman JE, et al. The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system[J]. Psychopharmacology, 1993, 112(1): S5-15. [15] Soderstrom H, Blennow K, Manhem A, et al. CSF studies in violent offenders. I. 5-HIAA as a negative and HVA as a positive predictor of psychopathy[J]. J Neural Transm, 2001, 108(7): 869-878. [16] Korpi ER, Goodman SI, Kleinman JE, et al. Relationship between tryptophan and serotonin concentrations in postmortem human brain[J]. Med Biol, 1987, 65(4): 217-220. [17] Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study[J]. Biol Psychiatry, 1997, 42(7): 529-545. [18] Erritzoe D, Rasmussen H, Kristiansen KT, et al. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients[J]. Neuropsychopharmacology, 2008, 33(10): 2435- 2441. [19] Labonte B, Bambico FR, Gobbi G, et al. Potentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex[J]. Naunyn Schmiedebergs Arch Pharmacol, 2009, 380(5): 383-397. [20] Su YA, Si TM, Zhou DF, et al. Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors[J]. Eur J Pharmacol, 2007,564(1/2/3): 123-130. [21] Kusljic S, Brosda J, Norman TR, et al. Brain serotonin depletion by lesions of the median raphe nucleus enhances the psychotomimetic action of phencyclidine, but not dizocilpine (MK-801), in rats[J]. Brain Res, 2005, 1049(2): 217-226. [22] Hashimoto K, Fujita Y, Iyo M, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors[J]. Neuro psychopharmacology, 2007, 32(3): 514-521. [23] Scheepers FE, Gispen-de Wied CC, Westenberg HG, et al. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients[J]. Neuro psychopharmacology, 2001, 25(4): 468-475. [24] Yuen EY, Li X, Wei J, et al. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses[J]. Mol Pharmacol, 2012, 81(2): 113-119. |